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Abstract
Background: Chronic atrial fibrillation is a prevalent cardiac disorder. The literature indicates
varying proportions of those treated with anticoagulants, and varying intensity of anticoagulation.
Electronic patient records are providing us with clinical data concerning management of
anticoagulant treatment in real-life practice that is useful for audits. We aimed to assess warfarin
treatment for chronic atrial fibrillation in primary health care with regard to prevalence, incidence,
the proportion treated and the quality of anticoagulation control.
Methods: Five primary health care centres in Stockholm with a registered population of 75146
participated in a one-year retrospective study of electronic patient records up until May 2000. All
patients over 18 years of age with an encounter labelled 'Atrial fibrillation' were identified, and all
records of patients on warfarin treatment were manually reviewed. Main outcome measures were
number of patients with chronic atrial fibrillation, number of patients on wafarin treatment, and
time within the therapeutic prothrombin range.
Results: In total, 419 patients had chronic atrial fibrillation, giving a prevalence of 0.60% (age-
adjusted 0.62%), the age group 65 years or older accounted for 91.6%, and 50.1% were women.
Out of these, 50.4% (211 patients) were established on warfarin treatment for chronic atrial
fibrillation (0.28% of the population), and there was a predominance of men (p = 0.02). Fifty-four
patients started treatment with warfarin for chronic atrial fibrillation (0.07% of the population).
Among 25 randomly selected patients on established treatment, the proportion of time within the
therapeutic range was 70.2%. Among 24 randomly selected patients starting treatment, the
proportion of time with therapeutic values was 54.2% and 66.9% the first and second months of
treatment, respectively.
Conclusions: Chronic atrial fibrillation is common among the elderly in primary health care, and
about half of these patients are treated with warfarin. It appears to be under-diagnosed, and may
also be under-treated. About two thirds of treatment time is spent within the therapeutic range,
and further improvement of the quality of anticoagulation control with warfarin may therefore be
hard to achieve.
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Background
Chronic atrial fibrillation (CAF) is an increasingly com-
mon cardiac disorder, with a prevalence of 0.9–1.2% in
the population [1,2], and it increases with age to 4.7% in
persons aged 65 years or older [3]. It is associated with an
annual incidence of thromboembolic stroke of 2–6% [4].
Oral anticoagulant drugs, i.e. vitamin K antagonists, have
been shown in well-designed clinical trials to have anti-
thrombotic efficacy in the prevention of embolic stroke in
patients with CAF, and they are medically and economi-
cally justified [4,5].
Warfarin is the standard anticoagulant drug used in Swe-
den. It is an efficacious anticoagulant, but it has a narrow
therapeutic range. A prothrombin time corresponding to
the International Normalized Ratio (INR) target of 2.5
(range 2–3) is recommended for most indications. The
anticoagulant response to warfarin is influenced by many
drug interactions and it is also affected by genetic and sig-
nificant environmental variability. A large number of
studies have demonstrated that the risk of bleeding com-
plications during treatment with warfarin increases drasti-
cally with an INR above the target value, and that the
antithrombotic effectiveness disappears with low INR val-
ues [6-8]. There is a relationship between the effectiveness
of warfarin and the proportion of time within the thera-
peutic range, and such estimates have therefore been used
as a measure of the quality of anticoagulation treatment
[9]. Several studies indicate that CAF is the most common
treatment diagnosis for warfarin [10,11]. The treatment is
considered fairly safe [12], although bleeding complica-
tions do occur [13]. The number of fatal or major bleeding
complications in clinical practice is about 1.7% per
patient-year [14]. Monitoring is frequently managed by
general practitioners (GP) [15]. There is ongoing discus-
sion concerning whether efficiency and safety can be kept
as low in primary health care (PHC) as at special clinics
for anticoagulation services.
The proportion of patients with CAF that are treated with
warfarin in primary health care settings is increasing [2],
but was shown in recent studies to vary widely, from 29–
97% [2,16-18]. A significant underuse of warfarin has
been reported [3,16,19]. The proportion of CAF patients
eligible for warfarin treatment varies from 41–61%
depending on the criteria used [13,20]. Contraindications
for warfarin treatment have been reported in 11–18% of
these patients [21,22].
The literature indicates a variable level of anticoagulation
intensity in real-life settings, with 43–81% of tests within
the therapeutic range [23-26], and the proportion of time
spent within the therapeutic range varying from 47–51%
[22,27]. Few studies have focused on monitoring in rou-
tine medical care, which is the predominant model of care
in many countries.
Patients on warfarin treatment in Stockholm are now
almost universally managed in PHC. Electronic patient
records (EPR) are currently used by almost all GPs in the
area, providing us with clinical data that is useful for
research. The general objective of this study was to study
the prevalence of CAF and its treatment with warfarin in
everyday clinical practice in PHC in a representative sam-
ple of clinics. The specific objective was to assess preva-
lence, incidence, the proportion treated and the quality of
anticoagulation control.
Methods
Selection of PHC centres
In order to compensate for local variations regarding the
population, we invited one PHC centre from each of the
five different health care districts in Stockholm County.
The EPR included the entire medical record and no paper
records were used. In each PHC centre one GP was
appointed as investigator. The total registered population
(calculated from a population registry maintained for
each GP) of the participating GPs comprised 75 146 indi-
viduals at the end of the study period.
Identifying patients
The initial selection criterion was all patients over 18 years
of age with an encounter labelled 'Atrial fibrillation' (code
I48- in the Swedish primary care version of ICD-10), dur-
ing a 12-month study period (June 1999 to May 2000).
The diagnosis of CAF was based on a clinical diagnosis
recorded by the GP, including persistent (i.e. en episode
of atrial fibrillation that has not reverted spontaneously to
sinus rhythm) and permanent atrial fibrillation (i.e. when
attempts at restoration of sinus rhythm have failed or
where the probability of successful cardio version is con-
sidered so low that no attempt is made) [28]. CAF is dis-
tinguished from 'Paroxysmal tachycardia' (code I47-,
including episodes of atrial fibrillation which are self-ter-
minating) in the current classification. The second selec-
tion criterion was all patients on warfarin treatment. This
was further specified as patients who were monitored with
INR values and  whose daily dosages of warfarin were
ordered by a GP at the PHC centre.
Data collection
The EPR systems were searched for code I48-, INR, age and
gender through their statistical modules for primary data
retrieval. The investigator thereafter manually reviewed all
EPRs including INR. Patients who had received a mini-
mum of 30 consecutive days of treatment during the study
period were included in the evaluation of proportion
treated and the quality of anticoagulation control. We
evaluated two groups of these patients, those with 1)BMC Clinical Pharmacology 2004, 4 http://www.biomedcentral.com/1472-6904/4/1
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established treatment, and those who 2) started treatment
during the study period. For the first group, all patients
with established warfarin treatment for CAF as the only
treatment diagnosis, or one of several treatment diag-
noses, were identified. The follow-up period for each of
these patients was 12 months for two centres and three
months for three centres, due to variable resources at the
centres. The follow-up continued until the last day of the
period or the date of discontinuation. For the second
group, all patients were identified who started warfarin
treatment for CAF as the only indication, or one of several
indications, during the study period. The follow-up
period was 90 days, starting with the first day of treat-
ment. For both these groups we randomly selected (using
a table of random numbers) five patients from each
health care centre (a total of 25 patients per group), and
they were subjected to a more detailed follow-up of INR
monitoring. For the selected patients (as described
above), information was collected concerning start date
for treatment, and data from each monitoring episode
(i.e. where PT was monitored and dosages given) includ-
ing date and INR value. The monitoring of anticoagulant
treatment was performed using INR, and the standard
range was from 2.0 to 3.0 INR.
Statistical analysis
The data were analysed using the SPSS® software pro-
gramme. The time spent in the INR target range was esti-
mated using linear interpolation [29], which assumes that
the INR between two consecutive measurements varies
linearly, including only INR values obtained at intervals
of eight weeks or less. Independent two-sample t-tests
were used to compare interval scaled variables. The Chi-
square test was used to test the distribution of cross-classi-
fied nominal variables. Ninety-five percent confidence
intervals (CI) were used.
Ethical considerations
This study was approved by the regional ethics committee
at Karolinska Institutet.
Results
Occurrence and proportion treated
The total registered population was 75 146. In total, 419
patients had CAF, giving a prevalence of 0.60% (age-
adjusted 0.62%), and 50.1% were women (Table 1). The
age group 65 years or older accounted for 91.6% of
patients with CAF, and 3.35% in the population. The
prevalence of CAF increased with increasing age, from
0.19% in the age group 45–64 years, to 5.59% in the age
group 85 years or older. Out of these, 211 patients were
on warfarin treatment for CAF, from 20 to 76 patients at
each PHC centre, 122 men and 89 women, and the mean
age was 73.7 (CI 95% 72.4; 75.1) (Table 1). Men were sig-
nificantly predominant (P = 0.02), accounting for 57.8%
(CI 95% 51.1; 64.4). The proportion treated with warfarin
was 50.4%, declining from 85.7% in the age group 45–64
years, to 18.8% in the age group 85 years or older. The
number of patients who started warfarin treatment for
CAF at the participating PHC centres was 54, accounting
for 25.6% of patients with CAF who were not on warfarin
treatment, and for 0.07% of the population.
Anticoagulation control
Among the 25 randomly selected patients established on
warfarin treatment, the median start year for the treatment
was 1997. Indications for warfarin treatment besides CAF
were found for five patients: prosthetic valve (three
patients), deep venous thrombosis (one), and cardiac inf-
arction (one). A total of 216 INR monitoring episodes
were identified. INR monitoring was done on average 1.3
times per month. The individual range for INR values was
2.0 to 3.0 INR for 24 of the patients, while one patient had
a lower range (1.7 to 2.5). The proportion of time within
the therapeutic range was 70.2% (Table 2), and the pro-
portion of values within the therapeutic range was 71.5%.
Values with a high bleeding risk (INR > 6.0) were not
found.
In the 25 randomly selected patients for whom warfarin
treatment was initiated during the study period, no treat-
ment diagnosis other than CAF was found. Data concern-
Table 1: Registered population, prevalence of chronic atrial fibrillation (CAF), patients established on warfarin treatment, and 
proportion treated, at five primary health care centres.
Age group <45 45–64 65–74 75–84 85+ Total Women
Registered population N 45294 18539 5125 4470 1718 75146 38851
Diagnosed CAF (n = 419) % <0.01 0.19 2.19 3.94 5.59 0.60 0.54
Age adjusted 0.62 0.60
Established treatment (n = 211) % <0.01 0.16 1.35 2.04 1.05 0.28 0.23
Age adjusted 0.28 0.25
Proportion treated % - 85.7 61.6 51.7 18.8 50.4 42.2*
* Significantly more men (p = 0.02)BMC Clinical Pharmacology 2004, 4 http://www.biomedcentral.com/1472-6904/4/1
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ing a total of 281 PT monitoring episodes were collected
(during the patients' first three months of treatment). PT
values were monitored on average 3.8 times per month.
The individual range for INR values was 2.0 to 3.0 for 24
of the patients, while one had a lower range (1.6 to 2.5).
The proportion of time within the therapeutic range was
54.2% and 75.4% the first and the third months of treat-
ment, respectively (Table 2). A value associated with a
high bleeding risk (INR > 6.0) was found in one episode.
Discussion
In this study we investigated warfarin treatment for CAF in
PHC with regard to occurrence and quality of anticoagu-
lation control. We found that CAF was common among
the elderly in primary health care. It appears to be under-
diagnosed, and it may also be under-treated. The quality
of anticoagulation control with warfarin may only be
improved to a limited extent. It was feasible to study war-
farin treatment for CAF by reusing information in elec-
tronic patient records, although retrieving INR values
required a manual review.
The prevalence figures for CAF in our study (0.6%, and
3.4% in 65+) are lower than in the studies mentioned
above (0.9–1.2%, and 4.7–5.9% in 65+) [1-3], especially
in patients 75 years or older, where our figures are signifi-
cantly lower. This suggests that there may be an under-
diagnosis of CAF in our study, or a selection bias in the
types of patients seen in PHC. Our figures represent the
prevalence in PHC (e.g. patients who actually were seen in
PHC and were treated for CAF) during the one-year study
period, and therefore are most probably underestimates
of the prevalence in the registered population. The rela-
tionship we found between prevalence and age is in
accord with findings in similar studies [1-3,20]. The prev-
alence of patients treated with warfarin for CAF has dif-
fered somewhat in studies done in recent years. Our figure
corresponds well with findings from other Swedish stud-
ies ranging from 0.3–0.4% [10,15], and from a Finnish
study where the reported prevalence was 0.3% [23].
The proportion treated with warfarin (50.4%) in our
study can be considered intermediate as compared with
studies mentioned above (29–97%) [2,16-18]. However,
considering the proportion of CAF patients who are found
eligible for warfarin treatment (41–61%) [3,20] and, on
the other hand, the proportion of patients with contrain-
dications for warfarin (11–18%) [21,22], our figures sug-
gest a minor underuse. The declining use of warfarin with
older age was somewhat more marked in our study com-
pared to findings in similar studies [2,16]. Numerous bar-
riers to warfarin treatment still exist in clinical practice,
even for eligible patients. These include practical, patient-
physician- and healthcare system-related barriers [30],
among which a major factor seems to be patients' unwill-
ingness to take warfarin [31]. Our figures may therefore
approach what can be achieved in everyday clinical prac-
tice. However, the extent to which these figures can be
improved is uncertain, since the number of eligible
patients is not known in our study. Further improvements
should probably include new approaches to CAF treat-
ment such as screening, disease-management teams in
PHC, and new strategies for patient education. These need
to be supported by the implementation of guidelines, and
by new incentives and a health care policy that solve the
problem of an increased clinical workload. The number of
patients on warfarin treatment and their frequent health
care contacts in PHC, a mean of more than once a month
in our study, point out a considerable workload related to
warfarin treatment, and this has received little attention.
Regarding the INR values, the quality of anticoagulation
control can be considered fairly high. The figures were
somewhat lower when initiating treatment, as expected.
Our figures on monitoring episodes within the therapeu-
tic range (71.5%) are in line with or are higher than fig-
ures reported in recent studies [23-26]. The proportion of
time spent in the therapeutic range (70.2%) is higher than
the figures mentioned above (47–51%) [27,22]. These fig-
ures may be improved further, as shown by the special
anticoagulation clinics [7], but probably only to a very
limited degree. This would requires a more organised
approach to anticoagulant management including com-
Table 2: Proportion of patient time (95 % confidence intervals) within International Normalized Ratio (INR) ranges for randomly 
selected patients started on, and established on, warfarin treatment for chronic atrial fibrillation. The standard INR range is 2.0 to 3.0, 
but there were some individual ranges.
Started on warfarin (N = 25) Established on warfarin 
(N = 24)
Treatment intervals (INR) 1st month 2nd month 3rd month
Super therapeutic (>3.0) 17.0 (7.9–26.1) 14.4 (6.6–22.2) 9.9 (1.3–18.5) 18.8 (8.0–29.7)
Therapeutic (2.0 – 3.0) 54.2 (42.1–66.4) 66.9 (54.3–79.7) 75.4 (61.1–89.8) 70.2 (59.9–80.4)
Sub therapeutic (<2.0) 28.7 (15.8–41.5) 18.6 (6.7–30.5) 14.6 (2.3–27.0) 11.0 (4.2–17.8)BMC Clinical Pharmacology 2004, 4 http://www.biomedcentral.com/1472-6904/4/1
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puter dosing systems and improved systems for follow-up
[32].
The major limitations of this study are that it is rather
small, the lack of clinical features regarding potential con-
traindications to anticoagulation, and the lack of informa-
tion about the presence or absence of risk factors for
stroke. An evaluation including the safety of warfarin
treatment in PHC would require a longer observation
time and a larger sample of patients than in this study.
Further, the study was conducted locally, and although we
tried to compensate for local variations, conclusions
about PHC in general must be made with caution. There
is no reason to believe that patients on warfarin treatment
were missed, as all patients receiving treatment (as
defined above) at the PHC centres are registered under
INR values in the laboratory module of the record sys-
tems. The actual therapeutic range for the patient is an
important factor, as it is sometimes individualised in clin-
ical practice, and this was taken into consideration in our
study. Most earlier studies are not based on PHC with a
registered population, a representative sample of patients,
and records from everyday clinical practice, which are the
advantages of our study.
Conclusions
CAF is common among the elderly in primary health care,
and about half of these patients are treated with warfarin.
It appears to be under-diagnosed, and may also be under-
treated. About two thirds of the treatment time is spent
within the therapeutic range, and a further improvement
of the quality of anticoagulation control with warfarin
treatment may therefore be hard to achieve. Given the fre-
quent monitoring episodes, there is a considerable work-
load related to warfarin treatment for CAF, both for
patients and for care providers.
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